Skip to main content

Advertisement

SpringerLink
Log in

Sustained Viral Response to Pegylated Interferon α-2b and Ribavirin in Chronic Hepatitis C Refractory to Prior Treatment

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) infection refractory to previous therapy is common. Treatment of patients with refractory disease is difficult and less studied. Pegylated interferon α-2b plus ribavirin is used for treatment of HCV patients naïve to therapy. We conducted a randomized study for refractory HCV patients using a high- vs. a low-dose pegylated interferon α-2b and ribavirin protocol. Our aim was (1) to determine the efficacy of pegylated interferon α-2b plus ribavirin to eradicate HCV in previously treated individuals and (2) to compare a low-dose to a high-dose regimen. One hundred fifty-two patients were initiated in the study, 112 (74%) were male and 40 (26%) female. Nineteen percent of patients obtained a sustained viral response (SVR) in the high-dose arm. Prior relapsers had the highest SVR rates: 50% in non-genotype 1 and 34% in genotype 1. The odds of achieving a SVR were six times higher in previous relapsers. The rate of SVR in genotype 1 patients who were nonresponders to prior therapy was only 8%. All patients who achieved a SVR had no detectable virus at week 24. However, only half of those who had undetectable viral titers at week 24 achieved a SVR. In conclusion, retreatment of patients with refractory hepatitis C infection with interferon α-2b and ribavirin combination therapy is well tolerated and gives modest response rates. The most important factor in predicting response to therapy is the manner of response to previous treatment. The likelihood of response to treatment can be predicted from the viral titers at 24 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tong MJ, El-Farra NS, Reikes AR, Co RL (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463–1466

    Article  PubMed  CAS  Google Scholar 

  2. Alter MJH (1997) Epidemiology of hepatitis C. Hepatology 16:62–65

    Article  Google Scholar 

  3. Centers for Disease Control and Prevention (1998) Recommendation for prevention and control of hepatitis C (HCV) infection and HCV related chronic disease. MMWR 4:1–38

    Google Scholar 

  4. Alter MJ, Krusyen-Mora D, Nainan OV, et al. (1999) The prevalence of hepatitis C in the United States, 1988 through 1994. N Engl J Med 341:556–562

    Article  PubMed  CAS  Google Scholar 

  5. Lauer GM, Walker BD (2001) Hepatitis C infection. N Engl J Med 345:41–52

    Article  PubMed  CAS  Google Scholar 

  6. Davis GL, Balart LA, Schiff ER, et al. (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321:1501–1506

    Article  PubMed  CAS  Google Scholar 

  7. Carithers RL Jr, Emerson SS (1997) Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 26(3; Suppl 1):83S–88S

    Article  PubMed  CAS  Google Scholar 

  8. Marcellin P, Boyer N, Gervais A, et al. (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127:875–871

    PubMed  CAS  Google Scholar 

  9. Keeffe EB, Hollinger FB (1997) Therapy of hepatitic C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 26(3; Suppl 1):101S–107S

    Article  PubMed  CAS  Google Scholar 

  10. McHutchison JG, Gordon SG, Schiff ER, et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492

    Article  PubMed  CAS  Google Scholar 

  11. Reichard O, Norkrans G, Fryden A, et al. (1998) Randomized double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83–87

    Article  PubMed  CAS  Google Scholar 

  12. Chemello L, Cavalletto L, Bernardinello E, et al. (1995) The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 23(Suppl 2):8–12

    PubMed  CAS  Google Scholar 

  13. Poynard T, Marcellin P, Lee SL, et al. (1998) Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426–1432

    Article  PubMed  CAS  Google Scholar 

  14. Zeuzem S, Feinman SV, Rasenack J, et al. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666–1672

    Article  PubMed  CAS  Google Scholar 

  15. Reddy KR, Wright TL, Pockros PJ, et al. (2001) Efficacy and safety of pegylated (40-kd) interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33:433–438

    Article  PubMed  CAS  Google Scholar 

  16. Lindsay KL, Trepo C, Heintgest P, et al. (2001) A randomized double blind trial comparing Pegylated interferon alfa-2b to interferon alfa-2b as enteral treatment for chronic hepatitis C. Hepatology 34:395–403

    Article  PubMed  CAS  Google Scholar 

  17. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. (2004) Pegineterferon Alfa-2a and Ribavirin in patients with chronic heapaitis C who have failed prior treatment. Gastroenterology 126:1015–1023

    Article  PubMed  CAS  Google Scholar 

  18. Dieperink E, Ho SB, Thuras P, Willenberg ML (2003) A prospective study of neuropsychiatric symptoms associated with interferon α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44:104–112

    Article  PubMed  CAS  Google Scholar 

  19. Schaefer M, Schmidt F, Folwaczyn C, et al. (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37:443–451

    Article  PubMed  CAS  Google Scholar 

  20. Fontana RJ, Moyer CA, Sonnad S, et al. (2001) Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 96:170–178

    Article  PubMed  CAS  Google Scholar 

  21. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750

    Article  PubMed  CAS  Google Scholar 

  22. Armstrong GL, Alte MJ, McQuillan GM, Margolis HS (2000) The post-evidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31:777–782

    Article  PubMed  CAS  Google Scholar 

  23. Obhrai J, Hall Y, Anand BS (2001) Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol 32:413–417

    Article  PubMed  CAS  Google Scholar 

  24. Bonis PA, Ioannechs JP, Cappelleri JC, et al. (1997) Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 26:1035–1044

    Article  PubMed  CAS  Google Scholar 

  25. Reichard O, Glauman H, Fryden A, et al. (1995) Two-year biochemical, virological, and histological follow-ups in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa 2b treatment. Hepatology 21:918

    Article  PubMed  CAS  Google Scholar 

  26. Nishisuchi S, Kurohi T, Nakatani S, et al. (1995) Randomized treatment of effects of interferon alpha or incidence of hepatocellular carcinoma in chronic hepatitis C with cirrhosis. Lancet 346:1051–1055

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported by Integrated Therapeutic Inc., a subsidiary of Schering Plough Research Institute (Kenilworth, NJ). This study was presented in part at the American College of Gastroenterology Meeting, Baltimore, Maryland, October 2003. We also acknowledge the Central Pennsylvania Study Group (R. Frederick [York, PA], S. Chen [Lancaster, PA], T. McDonald [Sayre, PA], H. Pickle [Allentown, PA], D. Rosenberg [Lancaster, PA], R. Bross [Danville, PA], and M. Smith [York, PA]) for their help in collecting the data from those enrolled in the study.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Pan State Milton S. Hershey Medical Center, Pennsylvania State University, P.O. Box 850, H045, Hershey, 17033-0850, Pennsylvania, USA

    A. Mathew, L. P. Peiffer, K. Rhoades & T. McGarrity

Authors
  1. A. Mathew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. P. Peiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Rhoades
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. McGarrity
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mathew, A., Peiffer, L.P., Rhoades, K. et al. Sustained Viral Response to Pegylated Interferon α-2b and Ribavirin in Chronic Hepatitis C Refractory to Prior Treatment. Dig Dis Sci 51, 1956–1961 (2006). https://doi.org/10.1007/s10620-006-9192-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9192-3

Keywords

Search

Navigation